VIDEO: Gastrointestinal response key focus of diabetes pipeline

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

 I'll keep it general, but I would say that, in the Type 2 space, it's largely looking at additional ways that we can work our own body's physiology. So, again, expanding on ways that we can affect the GI response, the gastrointestinal response. So we're gonna be looking at dual and triple incretin agents, we're gonna be looking at agents that affect amylin or affect glucagon as a metabolic generator of energy, which is pretty exciting. Certainly, in the Type 1 space, I think we've just opened a brand new wave of immune modulators and I think this is really important. I guess I will say, as someone that treats people with Type 1 and Type 2, let's be patient. We're always looking for a cure and we're getting significant progress, but please do our patients a favor and say, "This is a work in process," not promise them a cure sooner than we know, because, again, these are all still in development.